Sofinnova Capital X Fund closed at 472m
Paris-based life sciences venture capital firm Sofinnova Partners has closed the largest early-stage healthcare VC fund in Europe.
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 965 entries already.
Paris-based life sciences venture capital firm Sofinnova Partners has closed the largest early-stage healthcare VC fund in Europe.
German CureVac N.V. has withdrawn its application for market approval of its COVID-19 vaccine candidate and will focus on the development of a second-generation vaccine.
Leading industry leaders, SMEs representatives and academia are joining in Vienna, Austria, at the 14th European Forum for Industrial Biotechnology and the Bioeconomy (EFIB), from 6th to 7th of October, […]
Pharma giant AstraZeneca has submitted data to the US Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of its antibody duo AZD7442.
BionTech SE, which has been very successful in the field of corona vaccines, is starting phase II tests with its colorectal cancer candidate BNT122.
Advent France Biotechnologys has launched a second biotech seed fund with a first close at 86m. Since 2017, the French state fund has financed 15 startups in France, Spain, Belgium […]
A comparison of immune correlates of AstraZeneca’s Phase II/III COVID-19 vaccine trial shows what antibodiy titer is required to prevent symptomatic disease.
The EIF has invested 25m in the Prague-based i&i Biotech Fund I to boost biomedical tech transfer in Austria and Eastern Europe.
Following the $39bn Alexion buy-out completed in July, AstraZeneca plc announced it will invest 307m in the company’s producion site near Dublin.
UK-based DNA synthesis specialist Touchlight Ltd has extended a funding round to a current aggregate total of US $125m.